SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (28515)3/11/1999 8:48:00 PM
From: notyet  Read Replies (1) | Respond to of 32384
 
YAAHWN

It's a foregone conclusion that targretin will be approved for CTLC.
Alltough I would prefer a response rate of , uh ,100 %.
After approval stock won't do much. We need some good earnings.
I think downside is limited to 6 and I don't see a limit on the
upside.Still the LGND chart sucks . The stock is locked in some fucking range. Maybe it'll break out like IMNX did.
If it does I'll get drunk and let it all hang out on Yahoo where I can use handles and don't have to worry about the posted bullshit wrecking
my repu.




To: Henry Niman who wrote (28515)3/12/1999 11:33:00 PM
From: aknahow  Read Replies (1) | Respond to of 32384
 
O.T. but related to clinical trials. Have you or anyone else heard of a clinical trial in with an overall mortality target was pre established as a condition of termination of the trial, by the FDA? By overall I do mean the sum total of deaths in both the treatment as well as the placebo arm of the P III trial. This was apparently done to permit a trial to concluded with a smaller, than usual, number of accruals.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News